CL2018003769A1 - Una cepa del virus atenuado de la peste porcina africana desarrollada racionalmente que, protege contra la infección por el virus parental georgia 2007 aislado. - Google Patents
Una cepa del virus atenuado de la peste porcina africana desarrollada racionalmente que, protege contra la infección por el virus parental georgia 2007 aislado.Info
- Publication number
- CL2018003769A1 CL2018003769A1 CL2018003769A CL2018003769A CL2018003769A1 CL 2018003769 A1 CL2018003769 A1 CL 2018003769A1 CL 2018003769 A CL2018003769 A CL 2018003769A CL 2018003769 A CL2018003769 A CL 2018003769A CL 2018003769 A1 CL2018003769 A1 CL 2018003769A1
- Authority
- CL
- Chile
- Prior art keywords
- vppa
- georgia
- virus
- swine fever
- african swine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12061—Methods of inactivation or attenuation
- C12N2710/12062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12071—Demonstrated in vivo effect
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
- G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
Abstract
EL VIRUS DE LA PESTE PORCINA AFRICANA (VPPA, POR SUS SIGLAS EN INGLÉS) ES EL AGENTE ETIOLÓGICO DE UNA ENFERMEDAD VIRAL CONTAGIOSA, A MENUDO LETAL, DE LOS CERDOS DOMÉSTICOS. EL CONTROL DE LA PESTE PORCINA AFRICANA (ASF) SE HA VISTO OBSTACULIZADO POR LA FALTA DE DISPONIBILIDAD DE VACUNAS. LAS VACUNAS EXPERIMENTALES SE HAN DERIVADO DE VPPA ATENUADOS VIVOS, ADAPTADOS A CULTIVOS DE CÉLULAS O MODIFICADOS GENÉTICAMENTE; SIN EMBARGO, ESTAS VACUNAS SOLO TIENEN ÉXITO CUANDO PROTEGEN CONTRA VIRUS HOMÓLOGOS. HEMOS CONSTRUIDO UN VIRUS RECOMBINANTE D9GL/DUK DERIVADO DEL VIRUS VPPA GEORGIA 2007 (VPPA-G) ALTAMENTE VIRULENTO AL ELIMINAR LOS GENES ESPECÍFICOS ASOCIADOS A LA VIRULENCIA 9GL(B119L) Y EL UK(DP96R). IN VIVO, VPPA-G D9GL/DUK ADMINISTRADO POR VÍA INTRAMUSCULAR A LOS CERDOS, INCLUSO A DOSIS RELATIVAMENTE ALTAS (106HAD50) NO INDUCE ENFERMEDAD. ES IMPORTANTE DESTACAR QUE LOS ANIMALES INFECTADOS CON 104 O 106 HAD50 ESTÁN SÓLIDAMENTE PROTEGIDOS CONTRA LA PRESENTACIÓN DE LA ENFERMEDAD CLÍNICA CUANDO SE LOS DESAFÍA A LOS 28 DÍAS POSTERIORES A LA INFECCIÓN CON LA CEPA PARENTAL VIRULENTA GEORGIA 2007.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/200,407 US9808520B1 (en) | 2016-07-01 | 2016-07-01 | Rationally developed african swine fever attenuated virus strain protects against challenge with parental virus georgia 2007 isolate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018003769A1 true CL2018003769A1 (es) | 2019-03-22 |
Family
ID=60189680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018003769A CL2018003769A1 (es) | 2016-07-01 | 2018-12-21 | Una cepa del virus atenuado de la peste porcina africana desarrollada racionalmente que, protege contra la infección por el virus parental georgia 2007 aislado. |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US9808520B1 (es) |
| EP (1) | EP3478705B1 (es) |
| JP (1) | JP7121950B2 (es) |
| KR (1) | KR102443074B1 (es) |
| CN (1) | CN109952310B (es) |
| AU (1) | AU2017288932B2 (es) |
| BR (1) | BR112018076633A2 (es) |
| CA (1) | CA3029552A1 (es) |
| CL (1) | CL2018003769A1 (es) |
| DK (1) | DK3478705T5 (es) |
| EA (1) | EA201990085A1 (es) |
| ES (1) | ES2971606T3 (es) |
| FI (1) | FI3478705T3 (es) |
| GE (1) | GEP20207186B (es) |
| HR (1) | HRP20240254T1 (es) |
| HU (1) | HUE065240T2 (es) |
| LT (1) | LT3478705T (es) |
| MX (1) | MX2019000048A (es) |
| MY (1) | MY197376A (es) |
| PH (1) | PH12018502684B1 (es) |
| PL (1) | PL3478705T3 (es) |
| PT (1) | PT3478705T (es) |
| RS (1) | RS65124B1 (es) |
| SG (1) | SG11201811370XA (es) |
| SI (1) | SI3478705T1 (es) |
| UA (1) | UA125584C2 (es) |
| WO (1) | WO2018005358A1 (es) |
| ZA (1) | ZA201900259B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017128039A1 (zh) * | 2016-01-26 | 2017-08-03 | 浙江大学 | 基因组合及其用途 |
| US20220259569A1 (en) * | 2019-07-11 | 2022-08-18 | Aptimmune Biologics, Inc. | Methods for growing african swine fever virus in fetal porcine lung alveolar macrophage cells |
| CN110302371B (zh) * | 2019-08-21 | 2023-05-26 | 军事科学院军事医学研究院军事兽医研究所 | 灭活asfv作为复合疫苗的免疫攻毒保护成分的用途 |
| US11007263B2 (en) | 2019-09-24 | 2021-05-18 | The United States Of America, As Represented By The Secretary Of Agriculture | Development of a novel live attenuated African Swine Fever vaccine based in the deletion of gene I177L |
| JP7382628B2 (ja) * | 2019-10-11 | 2023-11-17 | 国立研究開発法人農業・食品産業技術総合研究機構 | アフリカ豚コレラウイルスの製造方法及び検出方法 |
| CN110760617B (zh) * | 2019-11-26 | 2021-12-21 | 华中农业大学 | 检测非洲猪瘟病毒野毒的实时荧光pcr引物探针组合及试剂盒 |
| KR20210087810A (ko) | 2020-01-03 | 2021-07-13 | 주식회사 중앙백신연구소 | 신규한 아프리카돼지열병의 예방 및 치료를 위한 바이러스 백신조성물 |
| CN111925994B (zh) * | 2020-07-03 | 2023-05-26 | 中国农业科学院兰州兽医研究所 | 一种dp71l基因缺失的重组非洲猪瘟病毒及其制备方法和应用 |
| CN111748563A (zh) * | 2020-07-10 | 2020-10-09 | 中国农业科学院兰州兽医研究所 | 非洲猪瘟基因缺失弱毒株的构建及其作为疫苗的应用 |
| CN112063592A (zh) * | 2020-07-10 | 2020-12-11 | 中国农业科学院兰州兽医研究所 | 非洲猪瘟多基因联合缺失减毒株的构建及作为疫苗的应用 |
| CN111996175B (zh) * | 2020-09-04 | 2023-11-21 | 军事科学院军事医学研究院军事兽医研究所 | 缺失e66l、i267l基因的非洲猪瘟减毒及活疫苗 |
| JP7477914B2 (ja) * | 2020-11-20 | 2024-05-02 | 国立研究開発法人農業・食品産業技術総合研究機構 | 不死化豚胎子小腸マクロファージ |
| EP4267965A1 (en) | 2020-12-24 | 2023-11-01 | Intervet International B.V. | African swine fever diva immunoassay |
| CN112852761B (zh) * | 2021-03-08 | 2022-08-23 | 中国农业科学院兰州兽医研究所 | 基因缺失减毒非洲猪瘟病毒株的构建及作为疫苗的应用 |
| CN115073558A (zh) * | 2021-03-10 | 2022-09-20 | 浙江海隆生物科技有限公司 | 一种重组的非洲猪瘟病毒dp96r亚单位蛋白及其制备方法和应用 |
| CN114392345B (zh) * | 2021-03-11 | 2023-08-25 | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | E199l蛋白在促进细胞凋亡中的用途及方法 |
| CN113061588B (zh) * | 2021-05-20 | 2023-08-01 | 军事科学院军事医学研究院军事兽医研究所 | 缺失i226r基因的非洲猪瘟病毒减毒株及其活疫苗 |
| US11801296B2 (en) | 2021-06-30 | 2023-10-31 | The United States Of America, As Represented By The Secretary Of Agriculture | Development of a novel live attenuated African swine fever vaccine based in the deletion of gene A137R |
| CN114107228B (zh) * | 2021-11-11 | 2023-06-13 | 中国农业科学院兰州兽医研究所 | 缺失十二个基因的减毒非洲猪瘟病毒株的构建及其作为疫苗的应用 |
| CN113831394B (zh) * | 2021-11-29 | 2022-04-12 | 中国人民解放军军事科学院军事医学研究院 | 一种非洲猪瘟病毒asfv基因的重组病毒组合及由其制备的疫苗 |
| WO2024137601A2 (en) * | 2022-12-21 | 2024-06-27 | Colorado State University Research Foundation | Systems, methods, and compositions for preparing vaccines comprising inactivated/attenuated pathogens |
| WO2024189198A1 (en) | 2023-03-16 | 2024-09-19 | Intervet International B.V. | A vaccine for protecting a pregnant swine against african swine fever |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8610106D0 (en) * | 1986-04-25 | 1986-05-29 | Central Blood Lab Authority | Human igm-producing heterohybridoma |
| US8846055B2 (en) * | 2006-05-30 | 2014-09-30 | The United States Of America, As Represented By The Secretary Of Agriculture | Virulence determinant within the E2 structural glycoprotein of classical swine fever virus |
| US9352032B2 (en) * | 2014-03-07 | 2016-05-31 | The United States Of America As Represented By The Secretary Of Agriculture | Live attenuated antigenically marked classical swine fever vaccine |
| GB201410971D0 (en) * | 2014-06-19 | 2014-08-06 | Pirbright Inst The | Vaccine |
| US9463234B2 (en) * | 2014-09-24 | 2016-10-11 | The United States Of America, As Represented By The Secretary Of Agriculture | Attenuated african swine fever virus strain induces protection against challenge with homologous virulent parental virus georgia 2007 isolate |
| US9528094B2 (en) * | 2014-11-10 | 2016-12-27 | The United States Of America, As Represented By The Secretary Of Agriculture | Attenuated African swine fever virus vaccine based in the deletion of MGF genes |
-
2016
- 2016-07-01 US US15/200,407 patent/US9808520B1/en active Active
-
2017
- 2017-06-26 DK DK17821008.4T patent/DK3478705T5/da active
- 2017-06-26 BR BR112018076633-0A patent/BR112018076633A2/pt unknown
- 2017-06-26 KR KR1020197003279A patent/KR102443074B1/ko active Active
- 2017-06-26 SG SG11201811370XA patent/SG11201811370XA/en unknown
- 2017-06-26 MX MX2019000048A patent/MX2019000048A/es unknown
- 2017-06-26 FI FIEP17821008.4T patent/FI3478705T3/fi active
- 2017-06-26 PL PL17821008.4T patent/PL3478705T3/pl unknown
- 2017-06-26 GE GEAP201714984A patent/GEP20207186B/en unknown
- 2017-06-26 CA CA3029552A patent/CA3029552A1/en active Pending
- 2017-06-26 SI SI201731488T patent/SI3478705T1/sl unknown
- 2017-06-26 JP JP2018568233A patent/JP7121950B2/ja active Active
- 2017-06-26 HU HUE17821008A patent/HUE065240T2/hu unknown
- 2017-06-26 LT LTEPPCT/US2017/039277T patent/LT3478705T/lt unknown
- 2017-06-26 ES ES17821008T patent/ES2971606T3/es active Active
- 2017-06-26 UA UAA201900970A patent/UA125584C2/uk unknown
- 2017-06-26 HR HRP20240254TT patent/HRP20240254T1/hr unknown
- 2017-06-26 WO PCT/US2017/039277 patent/WO2018005358A1/en unknown
- 2017-06-26 EA EA201990085A patent/EA201990085A1/ru unknown
- 2017-06-26 EP EP17821008.4A patent/EP3478705B1/en active Active
- 2017-06-26 CN CN201780053651.9A patent/CN109952310B/zh active Active
- 2017-06-26 MY MYPI2018002721A patent/MY197376A/en unknown
- 2017-06-26 PT PT178210084T patent/PT3478705T/pt unknown
- 2017-06-26 AU AU2017288932A patent/AU2017288932B2/en active Active
- 2017-06-26 PH PH1/2018/502684A patent/PH12018502684B1/en unknown
- 2017-06-26 RS RS20240124A patent/RS65124B1/sr unknown
-
2018
- 2018-12-21 CL CL2018003769A patent/CL2018003769A1/es unknown
-
2019
- 2019-01-15 ZA ZA2019/00259A patent/ZA201900259B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018003769A1 (es) | Una cepa del virus atenuado de la peste porcina africana desarrollada racionalmente que, protege contra la infección por el virus parental georgia 2007 aislado. | |
| Weger-Lucarelli et al. | A novel MVA vectored Chikungunya virus vaccine elicits protective immunity in mice | |
| PH12021550479A1 (en) | Dengue vaccine unit dose and administration thereof | |
| PE20150356A1 (es) | Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue | |
| AR080313A1 (es) | Composiciones de virus de moquillo canino (cdv) recombinante y sus usos | |
| BR112012021650A2 (pt) | "parvovírus recombinante atenuado, vacina para a proteção de animais contra infecção com parvovírus, método para a obtenção de um parvovírus recombinante, e, uso de uma vacina." | |
| Wang et al. | Immune responses in mice vaccinated with a suicidal DNA vaccine expressing the hemagglutinin glycoprotein from the peste des petits ruminants virus | |
| MX2017005687A (es) | Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia. | |
| PH12015501378B1 (en) | Porcine parvovirus 5a, methods of use and vaccine | |
| PH12017500216B1 (en) | Vaccine in serotype-9 fowl adenovirus recombinant vector | |
| Moreno et al. | Recombinant Rift Valley fever viruses encoding bluetongue virus (BTV) antigens: Immunity and efficacy studies upon a BTV-4 challenge | |
| CO6541529A2 (es) | Método, plasmideo y composición para inducir una respuesta inmune contra virus de la dengue basado en vacunas de adn y virus quimericos | |
| BR112016007390A2 (pt) | vacina de haemophilus parasuis sorotipo tipo quatro | |
| CO6700818A2 (es) | Vectores de parapoxvirus | |
| EA201890274A1 (ru) | Векторная система из аденовируса 9 птиц (fadv-9) и связанные способы | |
| NI201700080A (es) | Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas. | |
| GT201400199A (es) | Virus de la enfermedad de marek modificado y vacunas elaboradas con él | |
| Zhang et al. | Immunogenicity of a recombinant Sendai virus expressing the capsid precursor polypeptide of foot-and-mouth disease virus | |
| Dolzhikova et al. | Protective potential of structural proteins of the SARS-CoV-2 virus in protecting against COVID-19 | |
| AR082057A1 (es) | Vacunas de enterovirus para prevenir o tratar diabetes tipo 1 (i) | |
| RU2021104140A (ru) | Новый ослабленный штамм вируса и его применение в качестве вакцины |